Summit Therapeutics Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q4 2023). Net income: −$856M, trailing twelve months to Q2 2026. Free cash flow: −$460M, trailing twelve months to Q2 2026. EPS: −$1.11, trailing twelve months to Q2 2026.

SMMTSummit Therapeutics Inc.

Healthcare

$17.60-6.9% 1Y

$17.60

$12.4252 weeks$26.38

SMMT as reported

Summit Therapeutics Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q4 2023 · every figure below is as filed, with no scoring applied

Net income: −$856M
Net income · +15% year on year · trailing twelve months to Q2 2026
Free cash flow: −$460M
Free cash flow · +122% year on year · trailing twelve months to Q2 2026
EPS: −$1.11
EPS · +8.8% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SMMT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q4 2023 · 10 quarters behind
Net income	−$856M	+15%	Q2 2026
EPS	−$1.11	+8.8%	Q2 2026
Operating margin	−8085%	n/a	Q3 2022 · 15 quarters behind
Net margin	−9053%	n/a	Q3 2022 · 15 quarters behind
ROE	−250%	n/a	Q2 2026
ROA	−199%	n/a	Q2 2026
Free cash flow	−$460M	+122%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.